Quarterly report pursuant to Section 13 or 15(d)

Segment information (Tables)

Segment information (Tables)

3 Months Ended

Sep. 30, 2012

Financial Information Relating to Reportable Segments

Following is financial information relating to the Company’s reportable segments (in thousands):


	Quarter Ended
	September 30,
	2012			2011
External sales
Biotechnology	$	69,503		$	72,303
Hematology		5,522			5,293

Consolidated net sales	$	75,025		$	77,596

Earnings before income taxes
Biotechnology	$	36,994		$	39,984
Hematology		2,103			1,918

Segment earnings before income taxes		39,097			41,902
Unallocated corporate expenses and equity method investee losses		(1,111	)		(1,402	)

Consolidated earnings before income taxes	$	37,986		$	40,500

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details